Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Elanco Animal Health IncorporatedNYSE: ELAN
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns positive
Q3 FY2026 net income was $18M, compared with -$34M a year earlier. Trailing-twelve-month net income was -$103M. Over 3 fiscal years it compounded at +43.8% a year.
Context
- Net income amounted to 4.9% of revenue in FY2025, down 2.7 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of $599.57M (+358.4%) for the fiscal year ending Dec 2026, a step up from the -168.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $18M-66.7% QoQ
- Last fiscal yearDec 2025
- -$232M-168.6% YoY
- LTMSep 2026
- -$103M-386.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +152.9% | +138.7% | -14.2 pp |
| 1 year | -168.6% | +358.4% | +527.1 pp |
| 3-year CAGR | +43.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (232M) USD
- Year-over-year change
- -168.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (232M) | -168.6% |
| FY2024 | 2024-12-31 | 338M | +127.5% |
| FY2023 | 2023-12-31 | (1.23B) | -1478.2% |
| FY2022 | 2022-12-31 | (78M) | +83.5% |
| FY2021 | 2021-12-31 | (472M) | — |
Net Income vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 net income of $103M is the 4th largest of the 6 companies compared; the peer median is $1.18B.
- Its year-over-year change of -386.1% is the lowest of 6, against a peer median of -0.2%.
- Net income amounts to 2.0% of revenue for ELAN, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.17B | -80.7% | +7.9% | 4.8% | |
| LTM Jun 2026 | $2.62B | -0.2% | +8.2% | 27.5% | |
| LTM Sep 2026 | $1.18B | +15.1% | +16.0% | 25.4% | |
| LTM Sep 2026 | $103M | -386.1% | +43.8% | 2.0% | |
| LTM Mar 2026 | $95.23M | +199.6% | -0.6% | 6.3% | |
| LTM Aug 2026 | $56.14M | -94.6% | -29.8% | 6.4% | |
| Peer median (excluding ELAN) | $1.18B | -0.2% | +7.9% | 6.4% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (472M) | (78M) | (1.23B) | 338M | (232M) |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| Deferred Income Tax | (154M) | (57M) | (80M) | (112M) | (134M) |
| Stock-Based Compensation | 66M | 59M | 46M | 55M | 68M |
| Change in Working Capital | (87M) | (462M) | (300M) | 149M | 99M |
| Accounts Receivables | (3M) | 14M | (40M) | 12M | (12M) |
| Inventory | 27M | (269M) | (160M) | 44M | (57M) |
| Accounts Payables | (120M) | (98M) | (94M) | 82M | 147M |
| Other Working Capital | 9M | (109M) | (6M) | 11M | 21M |
| Other Non-Cash Items | 414M | 308M | 1.14B | (551M) | 79M |
| Operating Cash Flow | 483M | 452M | 271M | 541M | 560M |
| Capital Expenditures | (197M) | (184M) | (154M) | (147M) | (276M) |
| Acquisitions (Net) | (342M) | 13M | (19M) | 1.32B | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 9M | (8M) | (10M) | (14M) | (3M) |
| Investing Cash Flow | (530M) | (179M) | (169M) | 1.16B | (279M) |
| Debt Repayment | 177M | (517M) | (77M) | (1.48B) | (563M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33M | (32M) | (6M) | (17M) | 288M |
| Financing Cash Flow | 210M | (549M) | (83M) | (1.49B) | (275M) |
| Effect of Forex Changes | (31M) | (17M) | (12M) | (91M) | 71M |
| Net Change in Cash | 132M | (293M) | 7M | 116M | 77M |
| Free Cash Flow | 286M | 268M | 117M | 394M | 284M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.